| | Italy
Indication: Not yet registered for any indication.
Brand name: Ablify, Abilitat, Arpizole, and Arip-MT.
Regulatory status: Recommended for approval in schizophrenia by CPMP. No information available yet on potential bipolar filings.
Launch date: By end 2005 (schizophrenia).Committee for Proprietary Medicinal Products
| | | |
